Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer
Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma
DRUG: SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection|DRUG: Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection
ORR based on RECIST v1.1 assessment., All enrolled subjects were evaluated every 6 or 9 weeks starting with the first dose, up to 1 years
DCR based on RECIST v1.1 assessment, All enrolled subjects were evaluated every 6 or 9 weeks starting with the first dose, up to 1 years
Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.